Azitra Inc. (AZTR)
AMEX AMEX Primary Summary
Why Is Azitra (AZTR) Stock Down 75% Today?
Azitra (NYSEMKT: AZTR ) stock is falling hard on Wednesday morning after the biopharmaceutical company's shares underwent a massive rally yesterday. Azitra stock is down 75.2% as of Wednesday morning.
Why Is Azitra (AZTR) Stock Up 315% Today?
Azitra (NYSEMKT: AZTR ) stock is taking off on Tuesday after the early-stage biopharmaceutical company provided investors with updates on its patents. This covers the company's filaggrin-secreting strain of Staphylococcus epidermidis.
Azitra Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MO Matthew Okkerse Dauntless Investment Group LLC | 1,000 | $234 | $220 | -$14 | -5.98% |
Azitra Inc. (AZTR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Azitra Inc. ever had a stock split?
Azitra Inc. Profile
| Biotechnology Industry | Healthcare Sector | Francisco D. Salva CEO | AMEX Exchange | 05479L203 CUSIP |
| US Country | 12 Employees | - Last Dividend | 21 Aug 2025 Last Split | - IPO Date |
Overview
Azitra, Inc. is an early-stage biopharmaceutical company focused on pioneering advancements in precision dermatology. It harnesses the power of engineered proteins and live biotherapeutic products to develop innovative treatments for various skin diseases. Established in 2014 and headquartered in Branford, Connecticut, Azitra is at the forefront of addressing unmet needs in dermatological care through its cutting-edge research and clinical trials. In partnership with industry giant Bayer, Azitra seeks to transform therapeutic approaches to skin health.
Products and Services
- ATR-12
ATR-12 represents a significant breakthrough in the treatment of Netherton syndrome, a challenging and rare skin condition. It is a genetically modified strain of Staphylococcus epidermidis undergoing Phase Ib clinical trials. By leveraging the natural skin microflora, ATR-12 offers a promising therapeutic strategy that aligns with the company’s focus on precision dermatology.
- ATR-04
This innovative product targets the papulopustular rash often experienced by cancer patients who are treated with epidermal growth factor receptor inhibitors. ATR-04 is another genetically modified strain of Staphylococcus epidermidis, showcasing Azitra's dedication to creating tailored solutions for complex dermatological conditions faced by patients in oncology.
- ATR-01
Developed for the treatment of ichthyosis vulgaris, ATR-01 is an engineered recombinant human filaggrin protein. Ichthyosis vulgaris, a hereditary skin disorder resulting in dry, scaly skin, has had limited therapeutic options. ATR-01 reflects Azitra’s commitment to employing groundbreaking biotechnology to address such dermatological diseases by restoring protein function and skin barrier integrity.
